Table 2 Clinical outcomes in patients with different LVEF value
|  | Total (n = 74) | LVEF < 25% (n = 32) | LVEF25-35% (n = 42) | P |
|---|---|---|---|---|
Initial QRSd (ms) | 165.78 ± 19.73 | 168.75 ± 21.52 | 163.52 ± 18.19 | 0.262 |
Final QRSd (ms) | 113.16 ± 18.64 | 117.81 ± 17.09 | 109.62 ± 19.19 | 0.061 |
Initial NYHA Class | 3.50 ± 0.52 | 3.59 ± 0.48 | 3.43 ± 0.55 | 0.180 |
Final NYHA Class | 1.55 ± 0.62 | 1.78 ± 0.66 | 1.38 ± 0.54 | 0.005 |
Initial 6-MWD (m) | 140.41 ± 18.09 | 137.81 ± 15.40 | 142.38 ± 19.85 | 0.269 |
Final 6-MWD (m) | 373.51 ± 119.22 | 324.06 ± 128.34 | 411.19 ± 97.41 | 0.002 |
Initial LVEF (%) | 25.15 ± 5.26 | 20.50 ± 2.75 | 28.69 ± 3.73 |  < 0.001 |
Final LVEF (%) | 42.55 ± 11.84 | 37.78 ± 13.04 | 46.19 ± 9.47 | 0.003 |
Initial LVEDD (mm) | 65.81 ± 8.04 | 69.56 ± 6.77 | 62.95 ± 7.82 |  < 0.001 |
Final LVEDD (mm) | 56.26 ± 9.63 | 59.41 ± 11.00 | 53.86 ± 7.75 | 0.019 |
Initial LVESV (mL) | 196.87 ± 58.03 | 224.81 ± 50.65 | 170.93 ± 52.77 |  < 0.001 |
Final LVESV (mL) | 103.02 ± 72.22 | 134.00 ± 83.35 | 70.89 ± 38.89 | 0.001 |
Response ratio, n (%) | 61 (82.40%) | 23 (71.90%) | 38 (90.50%) | 0.076 |
Super-response ratio, n (%) | 53 (71.60%) | 20 (62.50%) | 33 (78.60%) | 0.129 |
LV complete reverse remodeling, n (%) | 25 (33.80%) | 7 (21.90%) | 18(42.90%) | 0.059 |
Re-hospitalization, n (%) | 24(32.40%) | 15(46.90%) | 9(21.40%) | 0.021 |